MedTrace Logo

G7 Dual Mobility With Vivacit-E or Longevity PMCF

NCT05548972 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 358

Last updated 2025-06-15

No results posted yet for this study

Summary

This study is a global, multi-center, prospective, non-controlled, non-randomized, post-market clinical follow-up study. The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System when used with the Vivacit-E or Longevity polyethylene hip bearing and instrumentation in primary total and revision (total) hip arthroplasty

Conditions

  • Hip Osteoarthritis
  • Rheumatoid Arthritis
  • Joint Diseases
  • Avascular Necrosis
  • Dislocation, Hip
  • Femoral Neck Fractures
  • Trochanteric Fractures
  • Revision Surgeries

Interventions

DEVICE

G7 Dual Mobility with Vivacit-E bearing

hip arthroplasty with G7 Dual Mobility Vivacit-E bearing

DEVICE

G7 Dual Mobility Longevity bearing

hip arthroplasty with G7 Dual Mobility Longevity bearing

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Hassan Achakri · Zimmer Biomet

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-20
Primary Completion
2037-01-31
Completion
2037-08-31
FDA Device
Yes

Countries

  • United States
  • Belgium
  • Italy
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05548972 on ClinicalTrials.gov